For a patient with stage IV colon cancer, which imaging, laboratory, and molecular tests should be ordered for staging and treatment planning?

Stage IV Colon Cancer Testing Panel

For stage IV colon cancer, immediately order MMR/MSI testing, complete RAS (KRAS/NRAS exons 2,3,4) and BRAF V600E mutation analysis, HER2 amplification testing (in RAS wild-type patients), and DPD deficiency testing before initiating fluoropyrimidine-based chemotherapy. 1

Essential Molecular Testing (Order at Diagnosis)

Mandatory Initial Panel

• MMR/MSI status - Required for both prognostic assessment and to identify candidates for immune checkpoint inhibitors 1
• RAS testing (KRAS and NRAS exons 2,3, and 4) - Mandatory before anti-EGFR monoclonal antibody therapy; can be performed on primary tumor or metastatic sites 1
• BRAF V600E mutation - Essential for prognostication and to identify candidates for cetuximab-encorafenib combination therapy 1
• DPD deficiency testing - Must be completed before initiating 5-fluorouracil or capecitabine-based chemotherapy 1

Secondary Molecular Testing

• HER2 amplification (IHC or FISH) - Recommended in RAS wild-type patients to identify candidates for HER2-targeted therapy in second-line and beyond 1
• NTRK fusion testing (when feasible) - Screen by IHC with NGS confirmation; influences treatment after progression on at least two lines of therapy 1

Important caveat: HER2 testing can be performed upfront for practical reasons, but will only influence treatment decisions after first-line progression 1

Staging Imaging Studies

Required Imaging

• Contrast-enhanced CT of thorax, abdomen, and pelvis - Primary staging modality with 90% negative predictive value for distant metastases 1, 2
• MRI of abdomen/pelvis with contrast - Preferred over CT when colorectal liver metastases appear amenable to local treatment; superior sensitivity (90-96%) versus CT (72-75%) for liver metastasis detection 1, 2

Conditional Imaging

• FDG-PET scan - Useful when tumor markers are elevated without CT evidence of metastatic disease, or to define extent of potentially resectable metastases 1

Critical technical point: Use the same radiological technique at baseline and for all subsequent response assessments 1

Laboratory Testing

Baseline Blood Work

• Complete blood count 1
• Comprehensive metabolic panel 1
• Carcinoembryonic antigen (CEA) - Mandatory 1
• CA 19-9 - Optional but recommended 1

Pathology Specimen Requirements

Ensure proper tissue handling: Fixation with 10% neutral buffered formalin (4% formaldehyde) for minimum 6 hours but no more than 48 hours 1. The pathologist must perform macro-dissection to maximize tumor cell content to >20% before DNA extraction 1.

Testing Sequence and Timing

The turnaround time for RAS testing should be approximately 10 days, as this directly impacts first-line therapy selection 1. MSI/MMR testing should be part of the initial molecular work-up since it determines eligibility for immune checkpoint inhibitors 1.

Common pitfall: Do not delay chemotherapy initiation waiting for NTRK or HER2 results, as these only influence treatment decisions in second-line or later settings 1.

Biomarkers NOT Recommended Outside Clinical Trials

Testing for ALK fusions, ROS1 fusions, PIK3CA mutations, and HER2 activating mutations should not be ordered outside of clinical trial protocols 1.